13 results about "Staphylococcal infections" patented technology

Provided herein are methods and systems for use in determining risk of a Staphylococcus infection, predicting efficacy of a Staphylococcus vaccine, and prognosing clinical outcomes on a subject exposed to Staphylococcus. Methods of treating subject identified as having or at risk of a Staphylococcus infection are further provided.

The invention belongs to the technical field of biological medicine, and particularly relates to a PDHC mutant, an immunogenic fragment and application, the PDHC mutant has amino acid mutation at at least one of the 214th site, the 274th site or the 294th site of the amino acid sequence shown in SEQ ID NO: 1, and the PDHC mutant is used for preventing or treating staphylococcus aureus (SA) infection and is an mRNA vaccine for preventing or treating staphylococcus aureus (SA) infection. The stability and immunogenicity of the staphylococcus aureus PDHC antigen are greatly improved, efficient targeted delivery of the antigen is achieved, and the immune effect of the vaccine is remarkably improved.

Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

The invention discloses an antigen protein as well as a preparation method and application thereof. The antigen protein comprises a soluble catalytic domain of the membrane protein LCP or a variant thereof. The antigen protein can be used for preventing and treating staphylococcus aureus infection, especially drug-resistant bacteria infection, and clinical related infectious diseases caused by the staphylococcus aureus infection, so that more stable broad-spectrum protection on staphylococcus aureus infection, especially drug-resistant staphylococcus aureus, is realized.

The application provides a recombinant chicken antibacterial peptide against drug-resistant Staphylococcus aureus and belongs to the field of veterinary technology. The recombinant chicken antibacterial peptide is expressed by genetically engineering recombinant Escherichia coli. Three active regions of natural chicken antibacterial peptides are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to the outer membrane protein of Staphylococcus aureus. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to drug-resistant Staphylococcus aureus is significantly lower than that of the three natural chicken antibacterial peptides, and the minimum inhibitory concentration of 8 μg / mL can completely inhibit the formation of a biological membrane of a drug-resistant Staphylococcus aureus USA300 strain. The recombinant chicken antibacterial peptide has good antibacterial effect on different drug-resistant Staphylococcus aureus isolated from a chicken farm, and can effectively solve the problem of drug-resistant Staphylococcus aureus infection in the chicken farm.

The invention discloses an application of a compound 3546847 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound 3546847 can neutralize the toxicity of staphylococcus aureus hemolysin, and has a protective effect on MRSA staphylococcus aureus USA300 infected mice. The compound 3546847 can be applied to preparation of anti-staphylococcus aureus hemolysin medicines and medicines for preventing or treating staphylococcus aureus infection. The new medicinal value of the compound 3546847 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound 3546847 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so as to relieve inflammatory injury.

This disclosure provides a method reducing the number of Staphylococcus aureus bacterial cells in a subject and a method of treating or preventing diseases or disorders caused by S. aureus. This disclosure also provides a method of diagnosis or prognosis of a disease or disorder caused by S. aureus.

The invention provides a medical application of resortanol in preparation of a staphylococcus aureus inhibitor, belongs to the technical field of biological medicines, and provides a novel medical application of resortanol, which can significantly inhibit growth of methicillin-resistant staphylococcus aureus and formation of a biofilm, and can inhibit the growth of methicillin-resistant staphylococcus aureus. The survival rate of methicillin-resistant staphylococcus aureus infection greater wax moth larvae can be obviously improved; the compound can be used for preparing a staphylococcus aureus inhibitor, a new candidate drug is provided for clinical treatment of multi-drug-resistant staphylococcus aureus infection, and the resorpterol and appropriate pharmaceutic adjuvants can be prepared into an injection for preparing drugs for systemic infection caused by methicillin-resistant staphylococcus aureus.

The invention discloses an application of a compound L604-0819 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound L604-0819 can neutralize the toxicity of staphylococcus aureus hemolysin, has a protective effect on MRSA staphylococcus aureus USA300 infected mice, and has the application of preparing a staphylococcus aureus hemolysin resisting medicine and a staphylococcus aureus infection preventing or treating medicine. According to the invention, the new medicinal value of the compound L604-0819 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound L604-0819 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so that inflammatory injury is relieved.

The present invention belongs to the fields of infectious microbial diseases and medicines. Provided is the use of compound 5928-0054 in the preparation of a drug against Staphylococcus aureus hemolysin. It is found that compound 5928-0054 can neutralize the toxicity of Staphylococcus aureus hemolysin, exhibits a protective effect on mice infected with MRSA Staphylococcus aureus USA300, and can be used in the preparation of a drug against Staphylococcus aureus hemolysin and a drug for preventing or treating Staphylococcus aureus infections. Compound 5928-0054 is found to have a new pharmaceutical value, i.e. providing a new drug for the prevention and treatment of Staphylococcus aureus infections. Compound 5928-0054 can neutralize hemolysin, the major virulence factor of Staphylococcus aureus, thereby alleviating inflammatory injuries.

The present application belongs to the technical field of biological medicine, and particularly relates to an antibacterial peptide with the functions of targeting Staphylococcus aureus and inhibiting quorum sensing signal and antibacterial effect. The present application first synthesizes a non-sulfur lactone AIP-III variant CP7 with the functions of targeting and inhibiting QS signal pathway in Staphylococcus aureus cells, and synthesizes an FP13-2 antibacterial peptide with broad-spectrum antibacterial activity, and then successfully synthesizes a composite peptide containing the CP7 domain and the FP13-2 domain. The composite peptide of the present application can target and kill Staphylococcus aureus, and is also effective for methicillin-resistant Staphylococcus aureus. The composite peptide of the present application has high antibacterial activity in vivo and in vitro, and has moderate toxicity. In addition, the mechanism of the composite peptide is different from that of traditional antibiotics, and the composite peptide is not prone to drug resistance, thereby providing certain guidance value for treating Staphylococcus aureus infection and drug-resistant bacteria.